Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major.
The consequences of transfusional iron overload on left ventricular diastolic filling have never been investigated systematically in patients with thalassemia major. In the present study, the pattern of left ventricular filling was assessed by Doppler echocardiography in 32 patients with thalassemia major (age, 17 +/- 5 years) who had not experienced symptoms of heart failure and had normal left ventricular systolic function. Data were compared with those obtained in 32 age-matched and sex-matched normal subjects. An abnormal Doppler pattern of left ventricular filling with increased flow velocity at mitral valve opening followed by an abrupt and premature decrease of flow velocity in early diastole was identified in the patients with thalassemia. Peak flow velocity in early diastole was increased in patients compared with controls (90 +/- 10 vs. 81 +/- 15 cm/sec; p less than 0.01), and rate of deceleration of flow velocity after the early diastolic peak and the ratio between the early and late (atrial) peaks of flow velocity were also increased (1,050 +/- 325 vs. 762 +/- 193 cm/sec2 and 2.7 +/- 0.7 vs. 2.2 +/- 0.5, respectively; p less than 0.001), whereas flow velocity deceleration time was reduced (97 +/- 22 vs. 119 +/- 19 msec; p less than 0.001). This Doppler pattern of diastolic filling is usually described as "restrictive" and reflects a decrease in left ventricular chamber compliance. A restrictive pattern of left ventricular filling was also identified in the subgroup of 16 study patients who had undergone optimal iron chelation therapy with deferoxamine.(ABSTRACT TRUNCATED AT 250 WORDS)
Spirito
P
P
Divisione di Cardiologia, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
Lupi
G
G
Melevendi
C
C
Vecchio
C
C
D000293:Adolescent; D000328:Adult; D002648:Child; D003326:Coronary Circulation / Q000187:drug effects; D003971:Diastole; D004452:Echocardiography; D015150:Echocardiography, Doppler; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D013789:Thalassemia / Q000188:drug therapy / Q000503:physiopathology*
D007502:Iron Chelating Agents